|
1
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Knyazev EN, Samatov TR, Fomicheva KA,
Nyushko KM, Alekseev BY and Shkurnikov MY: MicroRNA hsa-miR-4674 in
hemolysis-free blood plasma is associated with distant metastases
of prostatic cancer. Bull Exp Biol Med. 161:112–115. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang C, Ning S, Li Z, Qin X and Xu W:
miR-22 is down-regulated in esophageal squamous cell carcinoma and
inhibits cell migration and invasion. Cancer Cell Int. 14:1382014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Damavandi Z, Torkashvand S, Vasei M,
Soltani BM, Tavallaei M and Mowla SJ: Aberrant expression of breast
development-related microRNAs, miR-22, miR-132, and miR-212, in
breast tumor tissues. J Breast Cancer. 19:148–155. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang M, Jiang N, Cao QW and Sun Q: EDD1
predicts prognosis and regulates gastric cancer growth in vitro and
in vivo via miR-22. Biol Chem. Apr 28–2016.Epub ahead of print.
View Article : Google Scholar
|
|
6
|
Bar N and Dikstein R: miR-22 forms a
regulatory loop in PTEN/AKT pathway and modulates signaling
kinetics. PLoS One. 5:e108592010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Budd WT, Seashols-Williams SJ, Clark GC,
Weaver D, Calvert V, Petricoin E, Dragoescu EA, O'Hanlon K and
Zehner ZE: Dual action of miR-125b as a tumor suppressor and
oncomiR-22 promotes prostate cancer tumorigenesis. PLoS One.
10:e01423732015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu D, Takeshita F, Hino Y, Fukunaga S,
Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A,
et al: miR-22 represses cancer progression by inducing cellular
senescence. J Cell Biol. 193:409–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pasqualini L, Bu H, Puhr M, Narisu N,
Rainer J, Schlick B, Schäfer G, Angelova M, Trajanoski Z, Börno ST,
et al: miR-22 and miR-29a are members of the androgen receptor
cistrome modulating LAMC1 and Mcl-1 in prostate cancer. Mol
Endocrinol. 29:1037–1054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen B, Tang H, Liu X, Liu P, Yang L, Xie
X, Ye F, Song C, Xie X and Wei W: miR-22 as a prognostic factor
targets glucose transporter protein type 1 in breast cancer. Cancer
Lett. 356:410–417. 2015. View Article : Google Scholar
|
|
11
|
Xin M, Qiao Z, Li J, Liu J, Song S, Zhao
X, Miao P, Tang T, Wang L, Liu W, et al: miR-22 inhibits tumor
growth and metastasis by targeting ATP citrate lyase: Evidence in
osteosarcoma, prostate cancer, cervical cancer and lung cancer.
Oncotarget. 7:44252–44265. 2016.PubMed/NCBI
|
|
12
|
Yamakuchi M, Yagi S, Ito T and Lowenstein
CJ: MicroRNA-22 regulates hypoxia signaling in colon cancer cells.
PLoS One. 6:e202912011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang F, Hu Y, Liu HX and Wan YJ:
miR-22-silenced cyclin A expression in colon and liver cancer cells
is regulated by bile acid receptor. J Biol Chem. 290:6507–6515.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi C and Xu X: MicroRNA-22 is
down-regulated in hepatitis B virus-related hepatocellular
carcinoma. Biomed Pharmacother. 67:375–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li S, Hu R, Wang C, Guo F, Li X and Wang
S: miR-22 inhibits proliferation and invasion in estrogen receptor
α-positive endometrial endometrioid carcinomas cells. Mol Med Rep.
9:2393–2399. 2014.PubMed/NCBI
|
|
16
|
Ting Y, Medina DJ, Strair RK and Schaar
DG: Differentiation-associated miR-22 represses Max expression and
inhibits cell cycle progression. Biochem Biophys Res Commun.
394:606–611. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alvarez-Díaz S, Valle N, Ferrer-Mayorga G,
Lombardía L, Herrera M, Domínguez O, Segura MF, Bonilla F, Hernando
E and Muñoz A: MicroRNA-22 is induced by vitamin D and contributes
to its antiproliferative, antimigratory and gene regulatory effects
in colon cancer cells. Hum Mol Genet. 21:2157–2165. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pandey DP and Picard D: miR-22 inhibits
estrogen signaling by directly targeting the estrogen receptor
alpha mRNA. Mol Cell Biol. 29:3783–3790. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Yu H, Lu X, Zhang P, Wang M and Hu
Y: miR-22 suppresses the proliferation and invasion of gastric
cancer cells by inhibiting CD151. Biochem Biophys Res Commun.
445:175–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang Y, Liu X, Su B, Zhang Z, Zeng X, Lei
Y, Shan J, Wu Y, Tang H and Su Q: microRNA-22 acts as a metastasis
suppressor by targeting metadherin in gastric cancer. Mol Med Rep.
11:454–460. 2015.
|
|
21
|
Yang Q, Jiang W, Zhuang C, Geng Z, Hou C,
Huang D, Hu L and Wang X: microRNA-22 downregulation of galectin-9
influences lymphocyte apoptosis and tumor cell proliferation in
liver cancer. Oncol Rep. 34:1771–1778. 2015.PubMed/NCBI
|
|
22
|
Ahmad HM, Muiwo P, Ramachandran SS, Pandey
P, Gupta YK, Kumar L, Kulshreshtha R and Bhattacharya A: miR-22
regulates expression of oncogenic neuroepithelial transforming gene
1, NET1. FEBS J. 281:3904–3919. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu QF, Pan YW, Li LC, Zhou Z, Huang QL,
Pang JC, Zhu XP, Ren Y, Yang H, Ohgaki H, et al: miR-22 is
frequently downregulated in medulloblastomas and inhibits cell
proliferation via the novel target PAPST1. Brain Pathol.
24:568–583. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sreenivasan S, Thirumalai K, Danda R and
Krishnakumar S: Effect of curcumin on miRNA expression in human Y79
retinoblastoma cells. Curr Eye Res. 37:421–428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ling B, Wang GX, Long G, Qiu JH and Hu ZL:
Tumor suppressor miR-22 suppresses lung cancer cell progression
through post-transcriptional regulation of ErbB3. J Cancer Res Clin
Oncol. 138:1355–1361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Patel JB, Appaiah HN, Burnett RM,
Bhat-Nakshatri P, Wang G, Mehta R, Badve S, Thomson MJ, Hammond S,
Steeg P, et al: Control of EVI-1 oncogene expression in metastatic
breast cancer cells through microRNA miR-22. Oncogene.
30:1290–1301. 2011. View Article : Google Scholar
|
|
27
|
Li J, Liang S, Yu H, Zhang J, Ma D and Lu
X: An inhibitory effect of miR-22 on cell migration and invasion in
ovarian cancer. Gynecol Oncol. 119:543–548. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang R, Deng L, Zhao L, Li X, Zhang F,
Xia Y, Gao Y, Wang X and Sun B: miR-22 promotes HBV-related
hepatocellular carcinoma development in males. Clin Cancer Res.
17:5593–5603. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fan W, Huang J, Xiao H and Liang Z:
MicroRNA-22 is down-regulated in clear cell renal cell carcinoma,
and inhibits cell growth, migration and invasion by targeting PTEN.
Mol Med Rep. 13:4800–4806. 2016.PubMed/NCBI
|
|
30
|
Palacios F, Abreu C, Prieto D, Morande P,
Ruiz S, Fernández-Calero T, Naya H, Libisch G, Robello C, Landoni
AI, et al: Activation of the PI3K/AKT pathway by microRNA-22
results in CLL B-cell proliferation. Leukemia. 29:115–125. 2015.
View Article : Google Scholar
|
|
31
|
Tang J, Li Y, Wang J, Wen Z, Lai M and
Zhang H: Molecular mechanisms of microRNAs in regulating
epithelial-mesenchymal transitions in human cancers. Cancer Lett.
371:301–313. 2016. View Article : Google Scholar
|
|
32
|
Lu M, Jolly MK, Levine H, Onuchic JN and
Ben-Jacob E: MicroRNA-based regulation of
epithelial-hybrid-mesenchymal fate determination. Proc Natl Acad
Sci USA. 110:18144–18149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moes M, Le Béchec A, Crespo I, Laurini C,
Halavatyi A, Vetter G, Del Sol A and Friederich E: A novel network
integrating a miRNA-203/SNAI1 feedback loop which regulates
epithelial to mesenchymal transition. PLoS One. 7:e354402012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ding X, Park SI, McCauley LK and Wang CY:
Signaling between transforming growth factor β (TGF-β) and
transcription factor SNAI2 represses expression of microRNA miR-203
to promote epithelial-mesenchymal transition and tumor metastasis.
J Biol Chem. 288:10241–10253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiong J, Du Q and Liang Z:
Tumor-suppressive microRNA-22 inhibits the transcription of
E-box-containing c-Myc target genes by silencing c-Myc binding
protein. Oncogene. 29:4980–4988. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guo MM, Hu LH, Wang YQ, Chen P, Huang JG,
Lu N, He JH and Liao CG: miR-22 is down-regulated in gastric
cancer, and its overexpression inhibits cell migration and invasion
via targeting transcription factor Sp1. Med Oncol. 30:5422013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kong LM, Liao CG, Zhang Y, Xu J, Li Y,
Huang W, Zhang Y, Bian H and Chen ZN: A regulatory loop involving
miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer
invasion and metastasis. Cancer Res. 74:3764–3778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Choi JH, Hwang YP, Kim HG, Khanal T, Do
MT, Jin SW, Han HJ, Lee HS, Lee YC, Chung YC, et al: Saponins from
the roots of Platycodon grandiflorum suppresses TGFβ1-induced
epithelial-mesenchymal transition via repression of PI3K/Akt,
ERK1/2 and Smad2/3 pathway in human lung carcinoma A549 cells. Nutr
Cancer. 66:140–151. 2014. View Article : Google Scholar
|
|
39
|
Pandey AK, Zhang Y, Zhang S, Li Y,
Tucker-Kellogg G, Yang H and Jha S: TIP60-miR-22 axis as a
prognostic marker of breast cancer progression. Oncotarget.
6:41290–41306. 2015.PubMed/NCBI
|
|
40
|
Li B, Song Y, Liu TJ, Cui YB, Jiang Y, Xie
ZS and Xie SL: miRNA-22 suppresses colon cancer cell migration and
invasion by inhibiting the expression of T-cell lymphoma invasion
and metastasis 1 and matrix metalloproteinases 2 and 9. Oncol Rep.
29:1932–1938. 2013.PubMed/NCBI
|
|
41
|
Zuo QF, Cao LY, Yu T, Gong L, Wang LN,
Zhao YL, Xiao B and Zou QM: MicroRNA-22 inhibits tumor growth and
metastasis in gastric cancer by directly targeting MMP14 and Snail.
Cell Death Dis. 6:e20002015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang S, Zhang D, Yi C, Wang Y, Wang H and
Wang J: MicroRNA-22 functions as a tumor suppressor by targeting
SIRT1 in renal cell carcinoma. Oncol Rep. 35:559–567. 2016.
|
|
43
|
Su YH, Huang WC, Huang TH, Huang YJ, Sue
YK, Huynh TT, Hsiao M, Liu TZ, Wu AT and Lin CM: Folate deficient
tumor microenvironment promotes epithelial-to-mesenchymal
transition and cancer stem-like phenotypes. Oncotarget.
7:33246–33256. 2016.PubMed/NCBI
|
|
44
|
Ninomiya S, Tyybäkinoja A, Borze I, Räty
R, Saarinen-Pihkala UM, Usvasalo A, Elonen E and Knuutila S:
Integrated analysis of gene copy number, copy neutral LOH, and
microRNA profiles in adult acute lymphoblastic leukemia. Cytogenet
Genome Res. 136:246–255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shi TY, Cheng X, Yu KD, Sun MH, Shao ZM,
Wang MY, Zhu ML, He J, Li QX, Chen XJ, et al: Functional variants
in TNFAIP8 associated with cervical cancer susceptibility and
clinical outcomes. Carcinogenesis. 34:770–778. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu
S, Wu M, Pan Z and Zhou W: microRNA-22, downregulated in
hepatocellular carcinoma and correlated with prognosis, suppresses
cell proliferation and tumourigenicity. Br J Cancer. 103:1215–1220.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Parrish JK, Sechler M, Winn RA and
Jedlicka P: The histone demethylase KDM3A is a
microRNA-22-regulated tumor promoter in Ewing Sarcoma. Oncogene.
34:257–262. 2015. View Article : Google Scholar :
|
|
48
|
Lee JH, Park SJ, Jeong SY, Kim MJ, Jun S,
Lee HS, Chang IY, Lim SC, Yoon SP, Yong J, et al: MicroRNA-22
suppresses DNA repair and promotes genomic instability through
targeting of MDC1. Cancer Res. 75:1298–1310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Madzo J, Liu H, Rodriguez A, Vasanthakumar
A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T,
et al: Hydroxymethylation at gene regulatory regions directs
stem/early progenitor cell commitment during erythropoiesis. Cell
Rep. 6:231–244. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shen L, Wu H, Diep D, Yamaguchi S,
D'Alessio AC, Fung HL, Zhang K and Zhang Y: Genome-wide analysis
reveals TET- and TDG-dependent 5-methylcytosine oxidation dynamics.
Cell. 153:692–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Coutinho DF, Monte-Mór BC, Vianna DT,
Rouxinol ST, Batalha AB, Bueno AP, Boulhosa AM, Fernandez TS,
Pombo-de-Oliveira MS, Gutiyama LM, et al: TET2 expression level and
5-hydroxymethylcytosine are decreased in refractory cytopenia of
childhood. Leuk Res. 39:1103–1108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Song SJ, Poliseno L, Song MS, Ala U,
Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, et al:
MicroRNA-antagonism regulates breast cancer stemness and metastasis
via TET-family-dependent chromatin remodeling. Cell. 154:311–324.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Song SJ, Ito K, Ala U, Kats L, Webster K,
Sun SM, Jongen-Lavrencic M, Manova-Todorova K, Teruya-Feldstein J,
Avigan DE, et al: The oncogenic microRNA miR-22 targets the TET2
tumor suppressor to promote hematopoietic stem cell self-renewal
and transformation. Cell Stem Cell. 13:87–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jiang X, Hu C, Arnovitz S, Bugno J, Yu M,
Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, et al: miR-22 has a
potent anti-tumour role with therapeutic potential in acute myeloid
leukemia. Nat Commun. 7:114522016. View Article : Google Scholar
|
|
55
|
Tagawa T, Haraguchi T, Hiramatsu H,
Kobayashi K, Sakurai K, Inada K and Iba H: Multiple microRNAs
induced by Cdx1 suppress Cdx2 in human colorectal tumour cells.
Biochem J. 447:449–455. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Marzi MJ, Puggioni EM, Dall'Olio V, Bucci
G, Bernard L, Bianchi F, Crescenzi M, Di Fiore PP and Nicassio F:
Differentiation-associated microRNAs antagonize the Rb-E2F pathway
to restrict proliferation. J Cell Biol. 199:77–95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tang H, Kong Y, Guo J, Tang Y and Xie X,
Yang L, Su Q and Xie X: Diallyl disulfide suppresses proliferation
and induces apoptosis in human gastric cancer through Wnt-1
signaling pathway by up-regulation of miR-200b and miR-22. Cancer
Lett. 340:72–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li J, Zhang Y, Zhao J, Kong F and Chen Y:
Overexpression of miR-22 reverses paclitaxel-induced
chemoresistance through activation of PTEN signaling in p53-mutated
colon cancer cells. Mol Cell Biochem. 357:31–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tsuchiya N, Izumiya M, Ogata-Kawata H,
Okamoto K, Fujiwara Y, Nakai M, Okabe A, Schetter AJ, Bowman ED,
Midorikawa Y, et al: Tumor suppressor miR-22 determines
p53-dependent cellular fate through post-transcriptional regulation
of p21. Cancer Res. 71:4628–4639. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang H, Tang J, Li C, Kong J, Wang J, Wu
Y, Xu E and Lai M: miR-22 regulates 5-FU sensitivity by inhibiting
autophagy and promoting apoptosis in colorectal cancer cells.
Cancer Lett. 356:781–790. 2015. View Article : Google Scholar
|
|
61
|
Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang
Y, Wang Y, Zhao W and Wang W: miR-22 inhibits osteosarcoma cell
proliferation and migration by targeting HMGB1 and inhibiting
HMGB1-mediated autophagy. Tumour Biol. 35:7025–7034. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Nagaraja AK, Creighton CJ, Yu Z, Zhu H,
Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM,
et al: A link between miR-100 and FRAP1/mTOR in clear cell ovarian
cancer. Mol Endocrinol. 24:447–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kawahigashi Y, Mishima T, Mizuguchi Y,
Arima Y, Yokomuro S, Kanda T, Ishibashi O, Yoshida H, Tajiri T and
Takizawa T: MicroRNA profiling of human intrahepatic
cholangiocarcinoma cell lines reveals biliary epithelial
cell-specific microRNAs. J Nippon Med Sch. 76:188–197. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zekri AN, Youssef AS, El-Desouky ED, Ahmed
OS, Lotfy MM, Nassar AA and Bahnassey AA: Serum microRNA panels as
potential biomarkers for early detection of hepatocellular
carcinoma on top of HCV infection. Tumour Biol. 37:12273–12286.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Shin YM, Yun J, Lee OJ, Han HS, Lim SN, An
JY, Lee KH, Lee KM and Choe KH: Diagnostic value of circulating
extracellular miR-134, miR-185, and miR-22 levels in lung
adenocarcinoma-associated malignant pleural effusion. Cancer Res
Treat. 46:178–185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang C, Wang C, Chen X, Yang C, Li K,
Wang J, Dai J, Hu Z, Zhou X, Chen L, et al: Expression profile of
microRNAs in serum: A fingerprint for esophageal squamous cell
carcinoma. Clin Chem. 56:1871–1879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ganepola GA, Rutledge JR, Suman P,
Yiengpruksawan A and Chang DH: Novel blood-based microRNA biomarker
panel for early diagnosis of pancreatic cancer. World J
Gastrointest Oncol. 6:22–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Franchina T, Amodeo V, Bronte G, Savio G,
Ricciardi GR, Picciotto M, Russo A, Giordano A and Adamo V:
Circulating miR-22, miR-24 and miR-34a as novel predictive
biomarkers to pemetrexed-based chemotherapy in advanced non-small
cell lung cancer. J Cell Physiol. 229:97–99. 2014.
|
|
69
|
Wang W, Li F, Zhang Y, Tu Y, Yang Q and
Gao X: Reduced expression of miR-22 in gastric cancer is related to
clinicopathologic characteristics or patient prognosis. Diagn
Pathol. 8:1022013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhang G, Xia S, Tian H, Liu Z and Zhou T:
Clinical significance of miR-22 expression in patients with
colorectal cancer. Med Oncol. 29:3108–3112. 2012. View Article : Google Scholar : PubMed/NCBI
|
